Sumitomo Pharma Co. Ltd. announced that it will sell off two more of its subsidiaries, Sumitomo Pharma (China) Co. Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. (and their subsidiaries), to Marubeni Global Pharma Corp. April 1, as the Japanese pharma continues restructuring efforts from last year.
Tenvie Therapeutics Inc. has divulged NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of glaucoma, spinal cord injury, multiple sclerosis, Niemann-Pick disease, Alzheimer’s disease, amyotrophic lateral sclerosis, stroke and diabetic neuropathy, among others.
Previous work uncovered the role of the complement system in neuroinflammation and synaptic loss in neurodegenerative disorders such as Alzheimer’s disease (AD). The third component, C3, central in all complement activation pathways, has been proposed as a potential therapeutic target in AD.
Growing evidence exists on regulation of the chloride importer solute carrier family 12 member 2 (SLC12A2), also known as NKCC1, as a therapeutic approach to treat neurological disorders. Altered expression of NKCC1 leads to impaired intracellular chloride levels in neurons and imbalance in the excitatory-inhibitory axis in the brain.
At this week’s International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, researchers from Suntec Medical Inc. and collaborators presented a poster introducing a novel biologic (STM-003) targeting several pathological mechanisms involved in Alzheimer’s disease (AD), aiming to delay disease progression and improve cognitive function.
During the first oral sessions on Translational Drug Discovery at the 19th Alzheimer’s & Parkinson’s Diseases (ADPD) Conference, Beka Solomon from Tel Aviv University presented her work on the therapeutic potential of bone-marrow-derived microglia in Alzheimer’s disease (AD). “After working more than 30 years in immunotherapy, I decided to totally change the subject of the work,” Solomon told the audience.
GE Healthcare Technologies Inc. gained full ownership of Nihon Medi-Physics Co. Ltd. after acquiring the remaining 50% stake from Sumitomo Chemical Co. Ltd. on March 31.
Genzyme Corp. (Sanofi Genzyme) has divulged emopamil-binding protein (EBP) inhibitors reported to be useful for the treatment of multiple sclerosis, transverse myelitis, neuromyelitis optica, optic neuritis and Guillain-Barré syndrome.
Scientists at Beijing Wehand-Bio Pharmaceutical Co. Ltd. and Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College have synthesized phthalazinone compounds with neuroprotective effects reported to be useful for the treatment of hemorrhagic and ischemic stroke.
RSS
